Abdat R, Waldman RA, de Bedout V, et al. - Since bullous pemphigoid is an autoimmune blistering disorder that occurs mostly in the elderly and requires appropriate care, researchers described their experience using dupilumab in a series of bullous pemphigoid patients. Thirteen patients were identified in this analysis. The authors found that the average age of the patients was 76.8 and the average duration of bullous pemphigoid prior to the initiation of dupilumab was 28.8 months (range 1 to 60 months). Data reported that 92.3% (12/13) of individuals achieved either disease clearance or satisfactory response. Findings suggested that dupilumab can be an effective treatment for BP, resulting in disease clearance or satisfactory response in 92.3% of patients, including those who have failed conventional therapy previously. No adverse events have been recorded.